AR and prostate cancer: Resistance of the prostate cancer cells LNCaP to the AR inhibitor apalutamide is linked to TLE3 loss, and this is also the case for resistance to enzalutamide, a structurally close AR inhibitor, as shown in subsequent validation experiments [141].